Loading
A phase 3 trial at Iranian hospitals found that a locally made copy of bevacizumab controlled metastatic bowel cancer as well as the original.
126 patients with histologically verified colorectal cancer and at least one metastasis were randomised 2:1 to 5 mg/kg of the proposed biosimilar or the reference bevacizumab, each with FOLFIRI-3 every two weeks for one year. Progression-free survival was the primary endpoint, assessed per protocol with a non-inferiority margin of 1.44 for the hazard ratio.
Evidence that the bevacizumab made in Iran by AryoGen performs like the original, which matters in a country where imported originals have been hard to obtain.
Shares AryoGen Pharmed, Biosimilar.
Shares AryoGen Pharmed, Biosimilar.
Shares AryoGen Pharmed, Biosimilar.
Shares AryoGen Pharmed, Biosimilar, Bevacizumab.
Shares Biosimilar, Bevacizumab.
Shares Biosimilar, Bevacizumab.
Shares Stivant (AryoGen bevacizumab) against Avastin in metastatic colorectal cancer, AryoGen Pharmed, Bevacizumab, Colorectal cancer.
Shares Biosimilar, Bevacizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/